Engineering an indoleamine 2,3-dioxygenase immunotherapy via selective cysteine-to-serine mutations.

Abstract

Indoleamine 2,3-dioxygenase is an immunomodulatory enzyme that shows great promise when delivered exogenously as a protein therapeutic. However, IDO activity is under complex redox control, mediated in part by multiple cysteine residues within its primary sequence. We have characterized three IDO mutants in which solvent-accessible cysteine residues were mutated to chemically-similar serine residues, "IDO_C4S4" with C112S, C159S, C206S, and C308S mutations and "IDO_C5S3" with C112S, C159S, and C308S mutations based on prior reports that C206 is necessary for catalytic function, and IDO_C0S8, in which all cysteine residues were mutated to serines. IDO_C0S8 was expressed in poor yield and demonstrated less than 1% activity when compared to wild-type IDO. In contrast, IDO_C4S4 and IDO_C5S3 demonstrated robust enzymatic activity, though IDO_C5S3 had a slower V _max than wild-type and IDO_C4S4. Computational predictions and experimental measurements suggested a high degree of structural similarity between the wild-type IDO and IDO_C4S4, with subtle perturbation of α-helical content for IDO_C5S3. The structure of IDO_C0S8 was predicted to be significantly different than that of wild-type IDO. IDO_C4S4 and IDO_C5S3 were more stable than wild-type IDO over time at physiological, ambient, and reduced temperatures, likely due to diminished oxidation of the mutant IDO forms. Based on the increased V _max and robust thermal stability of IDO_C4S4, we fused it to the anchoring moiety galectin 3, to evaluate its effectiveness in a mouse model of psoriasis. The IDO_C4S4-galectin-3 fusion blunted the rate and severity of disease as compared to wild-type IDO-galectin-3 fusion. When compared to historical data with Cys-Ala IDO mutants, this study highlights the importance of employing amino acid substitution according to similarity in isosteric and isostructural shape to advance IDO as an immunomodulatory therapeutic.